Dishman Pharmaceutical and Chemicals, a Rs.990 crore pharma company from Ahmedabad, has achieved strong performance during the third quarter ended December 2011. It posted a consolidated net profit of Rs.16.72 crore as against Rs.1.62 crore in the corresponding period of last year. Its consolidated net sales increased by 14.5 per cent to Rs.265.46 crore from Rs.231.76 crore. EBDITA moved up by 95 per cent to Rs.61.51 crore from Rs.31.48 crore.

The sales from CRAMS business increased by 6.9 per cent to Rs.169.11 crore from Rs.158.18 crore in the similar period of last year and it contributed around 64 per cent to its net sales. Sales from other activities increased by 31 per cent to Rs.96.34 crore from Rs.73.58 crore. The company's profit from CRAMS went up to Rs.36.78 crore from Rs.8.49 crore.

For the nine months period ended December 2011, Dishman's net sales increased by 19.4 per cent, but its net profit declined sharply by 55.4 per cent to Rs.25.51 crore due to higher interest burden and lower operating income from Rs.57.22 crore in the same period of last year. Its interest cost went up by 45.3 per cent to Rs.45.18 crore from Rs.31.09 crore and its other operating income declined to Rs.2.10 crore from Rs.36.77 crore. The sales from CRAMS business improved by 7.6 per cent to Rs.496.68 crore from Rs.461.68 crore. Its sales from others moved up by 48.9 per cent to Rs.275.18 crore from Rs.184.77 crore.